Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Hepatitis B [https://www.who.int/news-room/fact-sheets/detail/hepatitis B]. Accessed 14/07/2023.
2. World Health Organization (WHO). Global hepatitis report. 2017;2017: 83.
3. Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of entecavir or tenofovir with pegylated interferon-α for long-term reduction in hepatitis B surface antigen levels: simultaneous, sequential, or add-on combination therapy. Int J Mol Sci. 2021;22:1456.
4. Grossi G, Viganò M, Loglio A, Lampertico P. Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). Liver Int. 2017;37 Suppl. 1:45–51.
5. Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14:434.